A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Trial Profile

A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Registrational
  • Acronyms Kinect 4
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 04 Dec 2017 Results published in the Neurocrine Biosciences Media Release
    • 04 Dec 2017 According to a Neurocrine Biosciences media release, new long-term data (n=163) was presented at the College of Neuropsychopharmacology (ACNP) Annual Meeting.
    • 29 Nov 2017 According to a Neurocrine Biosciences media release, new long-term data will be presented at the College of Neuropsychopharmacology (ACNP) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top